Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TESARO Inc    TSRO

TESARO INC (TSRO)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
90.45(c) 86.73(c) 86.32(c) 88(c) 86.6 Last
1 046 117 1 611 774 1 422 497 1 098 142 246 784 Volume
-0.70% -4.11% -0.47% +1.95% -1.59% Change
More quotes
Financials ($)
Sales 2017 225 M
EBIT 2017 -432 M
Net income 2017 -453 M
Finance 2017 415 M
Yield 2017 -
Sales 2018 427 M
EBIT 2018 -330 M
Net income 2018 -325 M
Finance 2018 234 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 19,4x
EV / Sales2018 10,7x
Capitalization 4 786 M
More Financials
Company
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products.It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.The company was founded by Leon Moulder, Jr., Mary Lynne Hedley,... 
Sector
Biotechnology & Medical Research
Calendar
11/29 | 09:50pmPresentation
More about the company
Surperformance© ratings of TESARO Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on TESARO INC
11/14 TESARO,INC. (NASDAQ : TSRO) Files An 8-K Departure of Directors or Certain Offic..
11/13 TESARO, INC. : Change in Directors or Principal Officers (form 8-K)
11/07 TESARO : Management's Discussion and Analysis of Financial Condition and Results..
11/07 TESARO : reports 3Q loss
11/07 TESARO Announces Third-Quarter 2017 Operating Results
11/02 EVOTEC : and TESARO Enter Strategic Partnership to Discover Novel Immuno-Oncolog..
11/01 TESARO : OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Canc..
10/30 TESARO,INC. (NASDAQ : TSRO) Files An 8-K Departure of Directors or Certain Offic..
10/30 EVOTEC : and Tesaro enter strategic partnership to discover novel immune oncolog..
10/30 OPKO HEALTH : Licensee TESARO Announces FDA Approval of VARUBI IV for Delayed Na..
More news
Sector news : Bio Therapeutic Drugs
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/15 Premarket analyst action - healthcare
11/13 YOUR DAILY PHARMA SCOOP : Regeneron's Appeal, Good News For Amgen, Bristol-Myers..
11/13 TESARO : Multiple Drivers Ahead, Not Pulling The Trigger
11/12 YOUR DAILY PHARMA SCOOP : Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soar..
Chart TESARO INC
Duration : Period :
TESARO Inc Technical Analysis Chart | TSRO | US8815691071 | 4-Traders
Technical analysis trends TESARO INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 66%
EPS Revisions
Managers
NameTitle
Leon O. Moulder Chief Executive Officer & Director
Mary Lynne Hedley President, Chief Operating Officer & Director
David M. Mott Chairman
Timothy R. Pearson Chief Financial Officer & Executive Vice President
Martin H. Huber Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
TESARO INC-35.81%4 786
GILEAD SCIENCES0.28%94 562
REGENERON PHARMACEUTICALS5.23%42 405
VERTEX PHARMACEUTICALS101.79%37 414
GENMAB-3.41%11 744
EXELIXIS, INC.66.00%7 642